Cell Genesys initiates pivotal trial of Gvax in prostate cancer
The study will compare the survival benefits of using Gvax vaccine for prostate cancer plus Taxotere (docetaxel) chemotherapy to Taxotere plus prednisone in patients with metastatic hormone-refractory prostate